Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. - Wikidata - wikimedia - TriplyDB

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

http://www.wikidata.org/entity/Q35268615

about

Major clinical research advances in gynecologic cancer in 2015 Current global status & impact of human papillomavirus vaccination: Implications for India Long-term efficacy and safety of human papillomavirus vaccination Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels Testing previous model predictions against new data on human papillomavirus vaccination program outcomes.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.The impact of HPV vaccination delays in China: lessons from HBV control programs.Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types Racial disparities in human papillomavirus vaccination: does access matter?Have preferences of girls changed almost 3 years after the much debated start of the HPV vaccination program in The Netherlands? A discrete choice experiment.Alternative dosage schedules with HPV virus-like particle vaccines.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Reducing HPV-associated cancer globally.Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study.Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania Sexually transmitted diseases treatment guidelines, 2015.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign.Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.Quantifying clinical HPV4 dose inefficiencies in a safety net population The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.Raising expectations for subunit vaccine Second-generation prophylactic HPV vaccines: successes and challenges.Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females Human papillomavirus vaccination: current indications and future directions Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland Major clinical research advances in gynecologic cancer in 2011.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine

P2860

Q28077183-3975213D-71AE-4425-AE7A-C134E7521E7B Q28079776-6A8A8FF7-6919-41FA-9F86-8E69BC6B1745 Q28081156-DFF12DC1-CA4D-4A76-918B-48A9945B60FA Q28088322-17E19A23-6051-41EB-A252-5294169732E5 Q28601706-6F961260-8A93-4D4B-AE9B-DE2D5F2690A2 Q28729883-58318AA7-BC26-4493-B8C0-1B7FB00E0B4B Q30251868-17E2A9E1-E22A-4319-9554-0619D802AC4F Q30300329-98DDE7D4-BC75-4969-90C5-CB65FEBF8197 Q30534669-715BF481-3D4A-4CE0-9FE4-66F58ECF69A5 Q30764433-8A056DAD-DAE4-45F7-8D23-27030474A0EA Q30780649-55C1A772-CAC1-4729-A617-490C2674358C Q30970916-50131F90-B982-4360-B74A-806AA48AAE43 Q30980654-DA020AA0-0D98-472D-B666-886D22CE58D5 Q31160912-DD1E101B-1927-46E2-9693-CCC443589620 Q33586562-85C6734F-A934-40D5-B28C-3F1F1C0DED54 Q33682928-E37B1FD6-AF89-47E2-AFA5-A6E43FEE9068 Q33759913-196972D5-6118-4030-A146-FC8BECC8350F Q34066068-440979AB-E9D9-4B8B-AA29-DF3FAC5EEB9B Q34102466-8478500C-2175-45C2-B2CF-03B6EF2F9C0F Q34199560-087B2E4B-3777-4DCA-89D5-E310DB056251 Q34244580-CDE67162-ECEF-42E2-9446-536E48F0ACF9 Q34347005-155BFC7A-6D59-4E1E-8C0B-2E462027D99F Q34475547-06295160-77D8-432C-969F-8D3C1B0DE777 Q34479272-2D18C084-1879-4398-BA25-B308D69B8462 Q34492140-1086E57E-404D-4D37-A0BB-218CC6561E57 Q34507291-13633B6B-50FA-4F71-8F86-FD1B23E79D9B Q34572303-802A612C-0568-4252-985C-98D59E549F0D Q34700425-C612ACFF-8C55-4688-9F49-1E651B1A8666 Q34852567-A096297D-A354-4227-9B40-8D02FF6A97EA Q34894228-C3E6A221-3138-4825-96FD-A7CABF1E8A32 Q35005743-57B5149B-FFFB-41C9-B799-4DCC5BC6A792 Q35040145-E4BA2A82-C8CB-4D38-97C4-417DABE80A97 Q35078557-A910E5A2-3B6F-4A3A-9884-C423AEBBD9E6 Q35452705-F1340743-D5A1-4919-8D88-519D19A0A9C0 Q35541886-E540AC07-41BB-4360-962A-D7A27F9C802A Q35550810-6FF27F30-4FCE-4A6D-BDF3-E2231C561B8B Q35558593-BE507154-B592-4AEE-BB9C-2894294E9116 Q35678090-9ED0F7EF-1287-4776-9ACA-A9AE848FE477 Q35758722-C6C591B8-735C-457E-9EDE-430F1B3FB53C Q35818648-18FE640F-B0A3-4716-B4E5-6379BA0ADB2D

P2860

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

http://www.wikidata.org/entity/Q35268615

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@ast

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@en

type

label

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@ast

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@en

prefLabel

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@ast

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@en

P1433

Q35268615-8A11E8EF-305C-4987-8796-4DD0DDF04DDC

P1476

Q35268615-24563BE0-5E0C-40D1-A3EA-97D9F7CA90CC

P2093

Q35268615-2773BAA3-74AF-460F-A6BB-2933DD2028A2

Q35268615-30CD4DF7-0E8B-47C3-9E24-A0F497203FA7

Q35268615-3721D530-FA23-452E-879A-F4B9901F5032

Q35268615-550B102F-5032-4F0B-93FE-1CD0D208FBC8

Q35268615-63546FA7-1061-49F9-88EB-4E29D7BAAEE4

Q35268615-6A86F5A3-CE77-4EBF-89E4-FC53D73EE1FD

Q35268615-6CDACC25-754E-4D02-941C-1552D97D95EE

Q35268615-78A87577-A439-4823-AA6D-87631E86EF1F

Q35268615-BD5B4531-8B51-4204-98E2-C144053E64D6

Q35268615-C666A37C-A125-4DA5-AB71-4D5701BF0D41

P2860

Q35268615-049F0A65-B234-47EE-A1B4-2C770D304802

Q35268615-16C5AE33-C879-473F-889F-3B77607C96C6

Q35268615-2927AE35-E90C-4CBC-AC50-B22CD6D498F6

Q35268615-37AC15B8-CDE1-4914-BF44-D9DF09A1E21A

Q35268615-580F8F42-1352-4204-B964-3AB021F5812B

Q35268615-6528E47E-6ADA-4676-A65C-BF8BC5C6A000

Q35268615-9948354B-0DD5-4A37-9CC6-BA531BF20B16

Q35268615-B2F340A8-182B-4BD7-BBD3-C0B1C91B746F

Q35268615-BE5CC7F0-9E8D-4F75-92D1-4123D0224703

Q35268615-C9FD9840-1888-4695-946C-824C21337976

P304

Q35268615-D774B9AA-42E9-44AD-93C2-B9AC17AEAFBC

P31

Q35268615-A226B048-1EA8-4DC3-931D-F5A62DDF635B

P356

Q35268615-756C9009-D2A8-4EDC-868A-8B2E17363DA0

P407

Q35268615-12EB9E73-C770-44CA-AB16-636223844479

P433

Q35268615-BDE688EC-0505-4668-A76A-292E5DF743C5

P478

Q35268615-BA9E69E0-F5CF-41AE-AFA2-94A07A05ABB6

P50

Q35268615-59BF5B2E-81B2-4D6E-A044-9650E7CC5217

Q35268615-6B6DEAAB-3790-4C4A-8F04-C8B1009929F0

Q35268615-CB95C509-1F96-4C4E-9BCC-69DA3FE0FB4B

Q35268615-E08108D8-3D4A-4818-92AB-2229ADC11EE6

P577

Q35268615-7A127771-79BB-4DF2-86BA-37E9C4140BED

P5875

Q35268615-39412BDE-4012-4C50-9469-33033CD4C407

P698

Q35268615-E9B6A904-120B-4641-9DB0-F268CDE173F7

P932

Q35268615-3AEFD89F-83A9-441E-B89F-5118D46ABAC3

P356

P1433

Journal of the National Cancer Institute

P1476

Proof-of-principle evaluation ...... f a bivalent HPV16/18 vaccine.

@en

P2093

Aimée R Kreimer

http://www.w3.org/2001/XMLSchema#string

CVT Vaccine Group

http://www.w3.org/2001/XMLSchema#string

Carolina Porras

http://www.w3.org/2001/XMLSchema#string

Diane Solomon

http://www.w3.org/2001/XMLSchema#string

Douglas R Lowy

http://www.w3.org/2001/XMLSchema#string

John Schussler

http://www.w3.org/2001/XMLSchema#string

John T Schiller

http://www.w3.org/2001/XMLSchema#string

Mark E Sherman

http://www.w3.org/2001/XMLSchema#string

Paula González

http://www.w3.org/2001/XMLSchema#string

Rolando Herrero

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.

Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses.

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

P304

1444-1451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR319

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Sholom Wacholder

Allan Hildesheim

Ana Cecilia Rodríguez

P577

2011-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51640195

http://www.w3.org/2001/XMLSchema#string

P698

21908768

http://www.w3.org/2001/XMLSchema#string

P932

3186781

http://www.w3.org/2001/XMLSchema#string